Bank of America Corp DE Reduces Stake in Certara, Inc. (NASDAQ:CERT)

Bank of America Corp DE lessened its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 46.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 660,799 shares of the company’s stock after selling 567,535 shares during the quarter. Bank of America Corp DE owned approximately 0.41% of Certara worth $7,038,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of CERT. BNP Paribas Financial Markets purchased a new stake in Certara in the 4th quarter worth $2,972,000. Ameriprise Financial Inc. grew its holdings in Certara by 864.0% during the 4th quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company’s stock valued at $40,253,000 after purchasing an additional 3,387,590 shares during the last quarter. Algert Global LLC purchased a new position in Certara during the 4th quarter valued at $662,000. ArrowMark Colorado Holdings LLC increased its stake in Certara by 164.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock worth $66,171,000 after buying an additional 3,861,674 shares during the period. Finally, Jane Street Group LLC boosted its holdings in shares of Certara by 60.5% in the fourth quarter. Jane Street Group LLC now owns 236,591 shares of the company’s stock valued at $2,520,000 after purchasing an additional 89,198 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. KeyCorp increased their price objective on shares of Certara from $15.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, April 16th. Barclays upgraded Certara from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $11.00 to $14.00 in a research report on Thursday, May 8th. William Blair reaffirmed a “market perform” rating on shares of Certara in a report on Thursday, February 27th. TD Cowen began coverage on Certara in a research report on Thursday, February 27th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Robert W. Baird boosted their target price on shares of Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, April 11th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Certara currently has an average rating of “Moderate Buy” and a consensus target price of $15.67.

Certara Trading Down 0.5%

Shares of CERT stock opened at $11.42 on Monday. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -57.10, a PEG ratio of 9.29 and a beta of 1.57. The company’s 50-day moving average price is $11.78 and its 200-day moving average price is $11.78. Certara, Inc. has a twelve month low of $8.64 and a twelve month high of $17.76.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.04. The firm had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. Certara’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 EPS. As a group, equities analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.